U.S. markets close in 5 hours 49 minutes
  • S&P 500

    4,448.44
    -25.31 (-0.57%)
     
  • Dow 30

    34,620.40
    -130.92 (-0.38%)
     
  • Nasdaq

    15,089.45
    -92.47 (-0.61%)
     
  • Russell 2000

    2,234.12
    +1.21 (+0.05%)
     
  • Crude Oil

    71.36
    -1.25 (-1.72%)
     
  • Gold

    1,753.30
    -3.40 (-0.19%)
     
  • Silver

    22.73
    -0.02 (-0.10%)
     
  • EUR/USD

    1.1758
    -0.0014 (-0.12%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • GBP/USD

    1.3768
    -0.0028 (-0.21%)
     
  • USD/JPY

    109.9650
    +0.2470 (+0.23%)
     
  • BTC-USD

    47,361.41
    -204.21 (-0.43%)
     
  • CMC Crypto 200

    1,204.03
    -21.51 (-1.75%)
     
  • FTSE 100

    7,007.08
    -20.40 (-0.29%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

Brickell Biotech to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on August 12, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BOULDER, Colo., July 29, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, announced today that it will report its financial results for the second quarter, ended June 30, 2021. Brickell’s management will host a conference call and webcast at 4:30 pm ET on Thursday, August 12th to discuss the financial results and recent corporate highlights.

To access the call, please dial 877-705-6003 in the U.S. or 201-493-6725 outside the U.S. and provide the conference ID number: 13720599. To access the live webcast, please go to the Investors section of Brickell’s website at https://ir.brickellbio.com/events-presentations. Following the live webcast, an archived version of the call will be available on the website.

About Brickell

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs. For more information, visit https://www.brickellbio.com.

Brickell Investor Contact:
Dan Ferry
LifeSci Advisors
(617) 430-7576
daniel@lifesciadvisors.com